Olympus Corporation
Olympus makes flexible GI endoscopes and medical imaging systems, the dominant supplier worldwide.
On the record
Checkpoint: Resolution of FDA import alert on Japan-made Olympus products and FY2026 Q3 earnings update
The call
Olympus still leads GI endoscopy by a wide margin, but an unresolved FDA import alert, duodenoscope lawsuits, and a disposable-scope rival are squeezing it at the same time.
Olympus is the world leader in flexible endoscopes (cameras doctors use to look inside stomachs and throats), controlling about 70 percent of the global market with specialized equipment and deep customer relationships built over decades. It is hard for others to copy because doctors need special training on Olympus machines, the company owns thousands of patents, and new competitors must pass strict medical safety rules. However, Olympus is in serious trouble right now: the US Food and Drug Administration blocked its Japan-made products from entering America in June 2025, the company is being sued over infections caused by its reusable scopes, and Boston Scientific is selling a throwaway alternative that sidesteps the infection problem. The biggest question is whether the FDA import ban gets lifted soon. If it does and stays lifted, Olympus can recover. If it stays in place or if Boston Scientific steals too much market share before Olympus fixes its problems, the company's profits will keep shrinking.
Why
01
AI pressure: Fujifilm and Pentax AI polyp-detection features matching Olympus CADDIE/OLYSENSE. Rivals now ship AI detection tools at rough parity, eroding Olympus's edge in software rather than hardware. Could AI do the core job? Unlikely.
02
Bigger players: Boston Scientific EXALT Model D single-use duodenoscope. Boston Scientific's disposable scope is winning cases where hospitals fear reusable-scope infection liability. Could a giant copy it? No, they are blocked.
03
What protects it. 70-75% global flexible-scope share, ~15,000 patents, and hospitals locked into EVIS X1 towers and training.
What would change this call
Whether the FDA import alert on Japan-made Olympus products is lifted or persists into 2027. Shows whether Olympus regains US market access or keeps losing revenue to blocked imports.
Whether duodenoscope/bronchoscope lawsuits consolidate into an MDL with disclosed reserves. Shows whether litigation risk is escalating into a material financial liability.
Whether Boston Scientific's EXALT Model D expands beyond duodenoscopes into colonoscopes or bronchoscopes. Shows whether single-use competition is spreading into Olympus's core scope categories.
Whether duodenoscope/bronchoscope lawsuits consolidate into an MDL with disclosed reserves. Shows whether litigation risk is escalating into a material financial liability.
Whether Boston Scientific's EXALT Model D expands beyond duodenoscopes into colonoscopes or bronchoscopes. Shows whether single-use competition is spreading into Olympus's core scope categories.
Key numbers
- FY2026 H1 revenue down 4.3% YoY, guidance cut
- FY2025 revenue ¥997.3 billion, up 8% YoY
- About $6.5B annual revenue, 49M colonoscopies performed cumulatively
Named risks
- FDA import alert since June 2025 blocking Japan-made products from US market remains unresolved as of mid-2026.
- Rising duodenoscope/bronchoscope litigation with possible MDL consolidation within 6 months of July 2026.
- Execution risk from ~2,000 job cuts and CEO transition during FY2026-2027 restructuring.
- Boston Scientific single-use duodenoscope share gains eroding Olympus's reusable-scope segment.
- Analyst sentiment softening after Goldman Sachs downgrade to Neutral in June 2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Boston Scientific | losing to | EXALT Model D single-use duodenoscope shipped, taking share in infection-liability segment as of 2026-07-24 |
| Fujifilm | contesting | One of the Big Three flexible GI endoscopy makers per 2026-04-16 comparison |
| PENTAX Medical (HOYA) | contesting | One of the Big Three flexible GI endoscopy makers per 2026-04-16 comparison |
| Karl Storz | contesting | Privately held German rival in rigid/surgical endoscopy and OR integration |
Questions people ask
- Is Olympus Corporation profitable in 2026?
- Olympus posted FY2025 revenue of ¥997.3 billion, up 8% YoY, but FY2026 H1 (six months to Sept 30, 2025) revenue fell 4.3% YoY and guidance was cut, with tariffs and regulatory headwinds cited, per FY2026 filings dated 2025-11-18.
- Who is Olympus Corporation's biggest competitor?
- Fujifilm and PENTAX Medical (HOYA) are Olympus's closest flexible GI endoscopy rivals, but Boston Scientific is the sharpest near-term threat, having shipped its EXALT Model D single-use duodenoscope and taken share in the infection-liability segment as of mid-2026.
- Could AI replace Olympus's endoscopy business?
- Unlikely soon: Olympus's own AI, OLYSENSE/CADDIE, is FDA-cleared (July 2024) and hardware-integrated into its EVIS X1/EXERA III towers, and it holds about 15,000 patents, meaning pure AI software vendors lack the hardware, regulatory clearance, and installed base to displace it.
- Why did Olympus cut 2,000 jobs?
- On 2025-11-07 Olympus announced plans to cut about 2,000 jobs (roughly 7% of its March 2025 headcount) as part of a new FY2026-FY2027 corporate strategy, alongside leadership changes including a CEO transition to Bob White and a new head of Gastrointestinal Solutions.
- What is the FDA import alert affecting Olympus?
- In June 2025 the FDA issued an import alert blocking numerous Olympus products manufactured in Japan from entering the US market; as of mid-2026 this alert remains active and is a binding constraint on Olympus's US revenue recovery.
- Is Olympus facing lawsuits over its duodenoscopes?
- Yes. A wrongful-death lawsuit alleging a fatal VRE infection from a reusable Olympus duodenoscope was filed on 2026-06-05 in the Western District of Washington, part of a renewed litigation wave following Class I/II recalls from 2023 to 2026; no MDL consolidation existed as of 2026-07.
Timeline
- 2026-06-05Wrongful-death VRE-infection lawsuit filed against Olympus duodenoscope in Western District of Washington
- 2026-06Goldman Sachs downgraded Olympus to Neutral from Buy
- 2026-02-02EAGLE trial (841 patients, 8 centers) published showing CADDIE AI improves lesion detection
- 2025-11-07Olympus announced ~2,000 job cuts (7% of headcount) and new FY2026-27 strategy with CEO transition
- 2025-09-30OLYSENSE/CADDIE AI platform commercially launched in US and Europe
- 2025-06FDA import alert issued, blocking Japan-manufactured Olympus products from US entry
- 2025-01Olympus acquired Sur Medical SpA's Olympus product-sales business in Chile
- 2024-07-12Olympus completed transfer of Orthopedic Business to Polaris Capital-affiliated SPCs
- 2024-07CADDIE received FDA 510(k) clearance and EU CE Mark
- 2022-08-28Olympus announced transfer of Evident (Scientific Solutions) subsidiary to Bain Capital
Revision history
24 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- gurufocus.com
- Olympus Announces Transfer of Subsidiary Evident to Bain Capital (2022-08-28)
- Olympus exits scientific instruments business (2022-08-29)
- Consolidated Financial Results for FY ended March 31, 2025
- Financial Results for Six Months of FY Ending March 31, 2026
- Olympus (7733) Q4 2025 Summary (2025-11-18)
- Corporate Fact Sheet
- What is Competitive Landscape of Olympus Company? (2026-03-19)
- Three Technologies that players in the endoscopy devices and equipment market are adopting (2023-04-25)
- Consolidated Company Outline (2025-03-30)
- Olympus Number of Employees (2026-07-06)
- Olympus to cut 2,000 jobs as it unveils new corporate strategy (2025-11-07)